Endovascular therapy for symptomatic atherosclerotic renal artery stenosis (ARAS) is common but is associated with a significant restenosis rate. This study evaluates the outcomes of percutaneous endoluminal therapy for symptomatic restenosis (>50% on angiography) after renal intervention.